Table 1 Clinical characteristics and immunization details of study subjects
From: The biochemical aftermath of anti-amyloid immunotherapy
Case ID | Expired age (years) | Gender | ApoE genotype | Disease Duration (years) | Imm. Dose (Ī¼g) | # of injections | Mean antibody response (ELISA units) | PIST (months) |
|---|---|---|---|---|---|---|---|---|
NDC | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
1-BSHRI | 77 | F | 2/3 | - | - | - | - | - |
2-BSHRI | 81 | F | 4/4 | - | - | - | - | - |
3-BSHRI | 83 | M | 3/4 | - | - | - | - | - |
4-BSHRI | 88 | M | 2/3 | - | - | - | - | - |
5-BSHRI | 81 | M | 3/3 | - | - | - | - | - |
Mean | 82 | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
AD | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā |
6-BSHRI | 76 | F | 4/4 | 6 | - | - | - | - |
7-BSHRI | 82 | M | 3/4 | 7 | - | - | - | - |
8-BSHRI | 86 | F | 3/4 | 5 | - | - | - | - |
9-BSHRI | 80 | F | 3/3 | 12 | - | - | - | - |
10-BSHRI | 85 | F | 3/3 | 9 | - | - | - | - |
11-BSHRI | 81 | F | 4/4 | 15 | - | - | - | - |
Mean | 82 | Ā | Ā | 9 | Ā | Ā | Ā | Ā |
Immunized AD* | Ā | Ā | Ā | Ā | Ā | Ā | Ā | |
12-USSM | 71 | F | 3/4 | 10 | 225 | 8 | 1:4072 | 44 |
13-USSM | 81 | M | n/a | 7 | 50 | 8 | 1:1707 | 57 |
14-USSM | 82 | M | 3/4 | 6 | 50 | 8 | 1:4374 | 60 |
15-USSM | 81 | M | 4/4 | 11 | 225 | 7 | 1:491 | 63 |
16-USSM | 88 | F | 3/3 | 11 | 50 | 7 | 1:137 | 86 |
19-UCSD | 78 | M | 3/4 | 5 | 50 | 1 | n/a | 36 |
20-UCSD | 86 | M | 3/4 | 9 | 50 | 1 | n/a | 60 |
Mean | 81 | Ā | Ā | 8 | Ā | 6 | Ā | 58 |
Immunized non-ADD* | Ā | Ā | Ā | Ā | Ā | Ā | Ā | |
21-USSM PSP | 79 | M | 2/3 | 6 | 50 | 8 | < 1:100 | 51 |
22-UCSD HS | 80 | M | 3/3 | 5 | 50 | 1 | n/a | 48 |